In this study, we examined the risk of colorectal and other secondary cancers for any tyrosine kinase inhibitor (TKI) therapy in BCR::ABL1 chronic myeloid leukemia (CML) patients using a comparative study design in 91 patients with CML and 76 controls and collected data on specific risk factors. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.